ADC Therapeutics SA
NYSE:ADCT
ADC Therapeutics SA
Net Income (Common)
ADC Therapeutics SA
Net Income (Common) Peer Comparison
Competitive Net Income (Common) Analysis
Latest Figures & CAGR of Competitors
Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
ADC Therapeutics SA
NYSE:ADCT
|
Net Income (Common)
$-240.1m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-14%
|
CAGR 10-Years
N/A
|
|
AC Immune SA
NASDAQ:ACIU
|
Net Income (Common)
CHf-54.2m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
N/A
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Net Income (Common)
$-153.6m
|
CAGR 3-Years
24%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Net Income (Common)
CHf10.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Idorsia Ltd
SIX:IDIA
|
Net Income (Common)
CHf-827.9m
|
CAGR 3-Years
-19%
|
CAGR 5-Years
-125%
|
CAGR 10-Years
N/A
|
|
Kuros Biosciences AG
SIX:KURN
|
Net Income (Common)
CHf-13.7m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
See Also
What is ADC Therapeutics SA's Net Income (Common)?
Net Income (Common)
-240.1m
USD
Based on the financial report for Dec 31, 2023, ADC Therapeutics SA's Net Income (Common) amounts to -240.1m USD.
What is ADC Therapeutics SA's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-14%
Over the last year, the Net Income (Common) growth was -54%. The average annual Net Income (Common) growth rates for ADC Therapeutics SA have been 1% over the past three years , -14% over the past five years .